Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
International Journal of Molecular Sciences · 19.07.2025 · 26 (14) · 6939
DOI: 10.3390/ijms26146939 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.07.2025. Verfasst von Alexander Yakobson und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
TP (tumor protein) 53 mutation status plays a critical role in cancer progression and may influence survival outcomes in non-small cell lung cancer (NSCLC) patients receiving immunotherapy. This study investigates the impact of TP53 mutation status and immunotherapy treatment on survival in NSCLC patients. This retrospective study analyzed NSCLC patients treated with pembrolizumab or ipilimumab plus nivolumab, stratified by TP53 mutation status and PD-L1 (programmed death-ligand 1) expression (50%). Survival outcomes (overall survival (OS) and progression free survival (PFS) were assessed using Kaplan–Meier curves and log-rank tests, with subgroup analysis by histological subtype. In squamous cell cancer (SCC) patients, no significant differences in OS or PFS were found based on TP53 mutation status or treatment type. A trend toward improved survival was observed with pembrolizumab (p = 0.088). In adenocarcinoma patients, significant differences in OS and PFS were observed based on TP53 mutation status. Pembrolizumab showed superior survival outcomes compared to ipilimumab plus nivolumab in TP53 wild-type patients (p < 0.001). PD-L1 ≥ 1% also predicted better outcomes, especially in adenocarcinoma patients. TP53 mutation status and immunotherapy type significantly influence survival outcomes in NSCLC, particularly in adenocarcinoma patients. Pembrolizumab demonstrated superior efficacy in TP53 wild-type patients, with PD-L1 expression further refining survival predictions. These findings underscore the importance of personalized treatment strategies based on TP53 status and PD-L1 expression in NSCLC. Further studies are needed to validate these results and optimize treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
- Edith Wolfson Medical Center, Oncology Institute, Holon 58220, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
- Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.
- Department of Oncology, Meir Medical Center, Kfar Saba 44180, Israel.
ORCID-Profile: Natalie Maimon Rabinovich, Fahmi Abu Ghalion, Abed Agbarya, Walid Shalata
Zitieren
APA
Yakobson, A., Brenner, R., Gothelf, I., Maimon Rabinovich, N., Cohen, A. Y., Abu Jama, A., Abu Yasin, N., Abu Ghalion, F., Agbarya, A., & Shalata, W. (2025). Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 26(14), 6939. https://doi.org/10.3390/ijms26146939
Vancouver
Yakobson A, Brenner R, Gothelf I, Maimon Rabinovich N, Cohen AY, Abu Jama A, et al. Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2025;26(14):6939. doi:10.3390/ijms26146939
BibTeX
@article{Yakobson2025,
author = {Yakobson, Alexander and Brenner, Ronen and Gothelf, Itamar and Maimon Rabinovich, Natalie and Cohen, Ahron Yehonatan and Abu Jama, Ashraf and Abu Yasin, Nashat and Abu Ghalion, Fahmi and Agbarya, Abed and Shalata, Walid},
title = {Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {14},
pages = {6939},
doi = {10.3390/ijms26146939}
}
EUVIMED